GSK has signed a new three-year agreement with Protas that aims to streamline trials across several core therapeutic areas.
Protas will provide a variety of scientifically led and operational expertise to improve trial quality, speed, efficiency and participation. This is driven by the team’s decades of experience designing and delivering innovative clinical trials, and its technology- and data-enabled approaches.
The agreement builds on an existing two-year relationship and will broaden the scope of work across numerous projects in phase 2 and 3 trials within GSK’s respiratory, immunology, inflammation, vaccines and infectious disease therapeutic areas.
Phillippa Brown, SVP, Head of Development Operations, GSK, said: “Our top priority is to accelerate development of life-changing medicines so they reach patients fast. Extending our collaboration with Protas will help us reimagine clinical trials to be even more precise and effective, making the most of technologies now available. This is one way we are accelerating our late-stage pipeline to help patients who are waiting.”
Prof Sir Martin Landray, Chief Executive Officer, Protas, said: “Our work with GSK embodies what Protas was set up to achieve for our customers and patients alike. With Protas’ fusion of smart trial design and innovative technology, we are able to unlock significant benefits in the quality, speed and efficiency of clinical trials and to improve access for participants.”